Sarah Brown

6.3k total citations · 1 hit paper
132 papers, 2.9k citations indexed

About

Sarah Brown is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Sarah Brown has authored 132 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 39 papers in Hematology and 36 papers in Molecular Biology. Recurrent topics in Sarah Brown's work include Multiple Myeloma Research and Treatments (36 papers), Protein Degradation and Inhibitors (24 papers) and Statistical Methods in Clinical Trials (11 papers). Sarah Brown is often cited by papers focused on Multiple Myeloma Research and Treatments (36 papers), Protein Degradation and Inhibitors (24 papers) and Statistical Methods in Clinical Trials (11 papers). Sarah Brown collaborates with scholars based in United Kingdom, United States and Australia. Sarah Brown's co-authors include Julia Brown, Vicky Napp, Phil Drew, Lindsay W. Turnbull, Andrew M. Hanby, Catherine Olivier, Ian Harvey, Michael Fenech, Jimmy W. Crott and David Jayne and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sarah Brown

123 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial

2015 329 citations Laura C. Coates, Sarah Brown et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Brown United Kingdom	25	938	585	536	496	496	132	2.9k
Jungnam Joo South Korea	35	1.2k 1.3×	539 0.9×	1.2k 2.3×	956 1.9×	234 0.5×	188	4.0k
Gyeong‐Won Lee South Korea	30	1.3k 1.4×	253 0.4×	936 1.7×	442 0.9×	223 0.4×	182	2.9k
Michele Nichelatti Italy	24	1.2k 1.3×	354 0.6×	1.1k 2.1×	311 0.6×	104 0.2×	108	3.9k
Kazuki Takada Japan	37	1.8k 2.0×	306 0.5×	1.2k 2.3×	327 0.7×	601 1.2×	149	4.3k
Bingshu E. Chen Canada	33	1.5k 1.6×	762 1.3×	551 1.0×	703 1.4×	209 0.4×	147	4.0k
Isildinha M. Reis United States	33	1.5k 1.6×	874 1.5×	641 1.2×	527 1.1×	359 0.7×	180	3.6k
Tobias Geisler Germany	39	583 0.6×	233 0.4×	381 0.7×	1.5k 3.1×	263 0.5×	233	5.8k
Qi Jiang China	27	3.6k 3.8×	492 0.8×	1.6k 3.0×	1.0k 2.0×	1.1k 2.3×	111	5.8k
Alan R. Schned United States	42	860 0.9×	622 1.1×	783 1.5×	1.7k 3.4×	246 0.5×	147	4.9k
Brian C.‐H. Chiu United States	33	1.2k 1.3×	393 0.7×	278 0.5×	295 0.6×	80 0.2×	104	3.2k

Countries citing papers authored by Sarah Brown

Since Specialization

Citations

This map shows the geographic impact of Sarah Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Brown more than expected).

Fields of papers citing papers by Sarah Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Brown. The network helps show where Sarah Brown may publish in the future.

Co-authorship network of co-authors of Sarah Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Brown. A scholar is included among the top collaborators of Sarah Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Brown. Sarah Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Reilly-Shah, Vikas N., Amit Saha, Sarah Brown, et al.. (2025). A Single‐Center Descriptive Analysis of Interventions for Hypotension in Children: A Retrospective Cohort Study. Pediatric Anesthesia. 35(12). 1016–1023. 1 indexed citations

Slevin, Finbar, Sarah Brown, Piet Ost, & Ann Henry. (2025). The POINTER-PC Study-determining Optimal Radiotherapy for Pelvic Nodal Recurrence in Prostate Cancer. Clinical Oncology. 46. 103912–103912. 1 indexed citations

Slevin, Finbar, et al.. (2025). Radiating Excellence: A Decade of Pioneering Radiotherapy Trials and Collaborative Leadership at Leeds Cancer Research UK Clinical Trials Unit. Clinical Oncology. 47. 103937–103937.

Mahmoud, Khaled, Michelle Wilson, Md Yuzaiful Md Yusof, et al.. (2024). O14 Rituximab objective outcome measures trial in SLE (ROOTS): outcomes of randomised and rescue rituximab therapy in a double-blind randomised placebo-controlled trial. SHILAP Revista de lepidopterología. A16.2–A17.

Price, James, Sarah Brown, Emma Hall, et al.. (2024). “Why am I still suffering?”: Experience of long-term fatigue and neurocognitive changes in oropharyngeal cancer survivors following (chemo)radiotherapy. Technical Innovations & Patient Support in Radiation Oncology. 30. 100241–100241. 1 indexed citations

Kaiser, Martin, Andrew Hall, Amy Holroyd, et al.. (2024). Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial. Blood. 144(Supplement 1). 3354–3354.

McHugh, Neil, Laura Bojke, Laura C. Coates, et al.. (2023). OP0271 INCIDENCE OF PSORIATIC ARTHRITIS AND PREVALENCE OF UNDIAGNOSED CASES IN A UK PRIMARY CARE POPULATION FOLLOWED PROSPECTIVELY FOR 2 YEARS - RESULTS FROM THE TUDOR RANDOMIZED CLINICAL TRIAL. Annals of the Rheumatic Diseases. 82. 178–179.

Brown, Sarah, Vicky M. Coyle, K. Franks, et al.. (2023). P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. Journal of Thoracic Oncology. 18(11). S296–S297. 2 indexed citations

Wootton, Sally, Marita Dale, Jennifer Alison, et al.. (2023). Mobile Health Pulmonary Rehabilitation Compared to a Center-Based Program for Cost-Effectiveness and Effects on Exercise Capacity, Health Status, and Quality of Life in People With Chronic Obstructive Pulmonary Disease: A Protocol for a Randomized Controlled Trial. Physical Therapy. 103(7). 6 indexed citations

10.

Slevin, Finbar, Sarah Brown, Joanne Haviland, et al.. (2023). Hitting the Target: Developing High-quality Evidence for Proton Beam Therapy Through Randomised Controlled Trials. Clinical Oncology. 36(2). 70–79. 2 indexed citations

11.

Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2023). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Journal of Clinical Oncology. 41(23). 3945–3955. 54 indexed citations

12.

Walker, Katrina, Samantha Hinsley, Anthony J. Chalmers, et al.. (2022). Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE. JCO Precision Oncology. 6(6). e2200133–e2200133. 2 indexed citations

13.

Zhong, Jim, Sarah Brown, Maria Aparecida Alves de Oliveira Serra, et al.. (2022). Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT). BMJ Open. 12(11). e068580–e068580. 5 indexed citations

14.

Hall, Andrew, Sarah Brown, Kevin Boyd, et al.. (2022). MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma. BMJ Open. 12(10). e062504–e062504. 2 indexed citations

15.

Homer, Victoria, Christina Yap, Simon Bond, et al.. (2022). Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 376. e068177–e068177. 17 indexed citations

16.

Brown, Sarah, Samantha Hinsley, Emma Hall, et al.. (2022). A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations. Clinical Cancer Research. 28(17). 3639–3651. 4 indexed citations

17.

Brown, Sarah, Samantha Hinsley, Louise Flanagan, et al.. (2021). MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. BMJ Open. 11(3). e046225–e046225. 17 indexed citations

18.

Bennett, Mike, et al.. (2009). Feasibility Study of Transcutaneous Electrical Nerve Stimulation (TENS) for Cancer Bone Pain. Journal of Pain. 11(4). 351–359. 43 indexed citations

19.

Vasudev, Naveen, Janet E. Brown, Sarah Brown, et al.. (2008). Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival. Clinical Cancer Research. 14(6). 1775–1781. 31 indexed citations

20.

Gilson, D., et al.. (1988). Therapeutic ratio of photodynamic therapy in the treatment of superficial tumours of skin and subcutaneous tissues in man. British Journal of Cancer. 58(5). 665–667. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact